chrisvoncsefalvay/vaers-outcomes huggingface dataset:
AT INJECTION SITE ARM BEGAN TO SWELL AND GET WARM. The swelling and redness didn't leave for about 3 weeks. The affected area stayed between elbow and shoulder on the back of the arm. Also patient noticed a red rash on abdomen about week after injection.
my left arm started to feel tingly, itchy, hot; my left arm started to feel tingly, itchy, hot; my left arm started to feel tingly, itchy, hot; Red; This spontaneous case was reported by a consumer and describes the occurrence of PARAESTHESIA (my left arm started to feel tingly, itchy, hot), PRURITUS (my left arm started to feel tingly, itchy, hot), FEELING HOT (my left arm started to feel tingly, itchy, hot) and ERYTHEMA (Red) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Jan-2021, the patient experienced PARAESTHESIA (my left arm started to feel tingly, itchy, hot), PRURITUS (my left arm started to feel tingly, itchy, hot), FEELING HOT (my left arm started to feel tingly, itchy, hot) and ERYTHEMA (Red). On 01-Feb-2021, PARAESTHESIA (my left arm started to feel tingly, itchy, hot), PRURITUS (my left arm started to feel tingly, itchy, hot) and FEELING HOT (my left arm started to feel tingly, itchy, hot) had resolved. At the time of the report, ERYTHEMA (Red) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications reported by investigator  No treatment medications provided by the reporter.
31 yo male received primary smallpox vaccination (SPV) on 3/4/2012. Approximately 3/15/2012 he awoke with 6/10 "indigestion-like" chest pain and shortness of breath. He was unable to return to sleep stating his pain was worse lying flat and eased by sitting up. He has no history of asthma, does not smoke, had no preceding viral illness, nor any lower extremity discomfort or activity that might predispose to thrombosis. Later that day his chest pain worsened to 8/10 climbing stairs with increased dyspnea ("gasping"). He presented to nearby ER with complaints of fever/chills, fatigue, chest pain, dry cough, wheezing, shortness of breath, and redness-swelling to left arm vaccination site. His admission note made no mention of chest pain or dyspnea but concentrated on admission for an "infected vaccination site" describing increasing erythema and redness to left arm up to shoulder and into axilla and chest x 48 hours. His SPV site was described as tender with black eschar and encircling erythema. He was admitted x 3 days with a diagnosis of cellulitis, given IV ROCEPHIN 1 gram every 12 hours, and oral TYLENOL 650 mg and BENADRYL as needed. Because the patient still complained of cough and shortness of breath, he was provided nasal O2 and a lung CT was obtained. The radiologist noted nonspecific abnormal lymph nodes in left axilla. Bibasilar dependent atelectasis in both lung bases. Otherwise CT chest without the contrast is unremarkable, and according to the attending physician ruled out any chest abnormality including any kind of clot. His EKG showed NSR without ischemic changes, CBC/WBC and electrolytes were normal. There were no cardiac studies (troponin, CK-MB, etc.) performed. His CXR was normal. A CT scan of his chest to rule out thrombi as potential cause of shortness of breath and cough was normal with nonspecific abnormal lymph nodes in left axilla and bibasilar dependent atelectasis, no clot. O2 sats were normal. He was diagnosed with cellulitis left shoulder and released 3 days later with resolving site inflammation but had a persistent dry cough and sensation of shortness of breath. The patient states that his chest pain and dyspnea slowly lessened from onset and by the 17th was total resolved. His office contacted the health care office for chest pain after receipt of smallpox vaccination. Correspondence occurred between health care providers and this patient's physicians for possible myopericarditis following receipt of SPV. The health care Vaccine-Associated Myopericarditis Algorithm was provided and cardiac enzymes were requested. Patient left in April 2012 completing his assignment without sequelae. A follow up interview by health care identified patient healthy, no further chest pain or shortness of breath. He runs 1.5 miles 2-4 x/wk without incident. He completed his annual PT 2 weeks ago passing easily.
Didn't feel good; This spontaneous case was received on 15-Oct-2022 from non-healthcare professional (consumer) via Communications (reference number: SEQW22-04546) and concerned a female patient of unspecified age.  The patient's medical history and concomitant medications were not reported  On unspecified date, the patient was vaccinated with influenza vaccine (brand not specified; dose, route of administration, anatomical location, and indication: not reported). The batch number was not reported.  On unspecified date, after receiving the influenza vaccine, the patient didn't feel good.  On an unspecified date, after a couple of days, the patient recovered from the event.  The outcome of the event was not reported.  The reporter assessed the event of 'feeling unwell' as related to influenza vaccine. The patient usually does not feel good for a couple of days after she has the flu shot.  The case was assessed as non-serious.  This case is linked to case 202205638  (the same patient).  Company comment: Due to lack of information and unclear temporal relationship, causality for feeling unwell is assessed as unassessable.; Reporter's Comments: The patient usually does not feel good for a couple of days after she has the flu shot.; Sender's Comments: Due to lack of information and unclear temporal relationship, causality for feeling unwell is assessed as unassessable.
Report from assisted living. starting 2-15-2021 Client was confused. UTI ruled out. She was wandering places she should not. She was in another residents room. She is speaking to staff in another language. VERY confused.  Trying to eat her napkin. Unable to dress herself. 2-16-2021 incontinent. not normal for her. unable to stand up. very weak. still very confused. left arm pain. falling asleep mid sentence.
Migraine that turned into headache that lasted 2 and a half days. Shoulder pain
Information has been received from a medical assistant referring to unspecified patients of unknown age and gender. The patients' pertinent medical history, drug reactions/allergies and concomitant medication were not provided. On unknown dates, the patients were vaccinated with improperly stored doses of ROTATEQ (lot # L008034, expiration date 05-AUG-2016, lot # L006184, expiration date 13-DEC-2016; dose was unknown) orally. No adverse effects was reported. No product quality complaint (PQC) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
Patient reports swelling and redness present at injection site.  Hot to the touch.  Application of cold has helped symptoms.
PATIENT CAME IN ASKING FOR SHINGRIX VACCINE. VACCINE WAS ADMINISTERED TO PATIENT, THEN PATIENT ASKED FOR DOCUMENTATION. I LOOKED UP HIS VACCINE REGISTRY TO PRINT, THEN REALIZED PATIENT FINISHED THE SERIES 3 YEARS AGO IN 2018. I ADVISED PATIENT THAT HE FINISHED THE SERIES AND THIS NOW SERVES AS A THIRD DOSE. WHEN ASKED WHY PATIENT CAME IN FOR VACCINE, PATIENT STATED THAT HE BELEIVED HE WAS SUPPOSED TO GET IT EVERY SINGLE YEAR. I ADVISED PATIENT HE IS NOW GOOD FOR LIFE, AND DOES NOT NEED TO GET THE SHINGRIX VACCINE AGAIN.
Symptoms first began approximately 12.5 hours after receiving the vaccine. Symptoms include mild nausea that comes and goes, chills that lasted about 4 hours, nasal congestion, constant sore arm, tiredness, headache, and muscle aches. Treated with ibuprofen and then Tylenol, which relieved the headache and muscle aches slightly.
Narrative:  COVID infection following COVID vaccine series 05/12. Pfizer. dose #1 06/02, Pfizer, dose #2 08/23 pt cc: fever, rhinorrea, left sided weakness , fatigue, cough, myalgias, chills, headache, exposure: unknown 08/25 COVID swab, result: detected 08/25 SARS-COV-2 Variant Sequencing result: pending 09/08 pt admit to medicine cc: SOB dx: COVID-19 complicated with multifocal pneumonia/pneumonitis, acute hypoxemic resp failure, bilateral pulmonary embolism (PEs). Likely secondary to COVID-19 infection, transaminitis/chemical and/or COVID-19 induced hepatitis LOS:9 days 09/08 COVID swab, result: detected 09/08 DDIMER result: 60.11 09/08 LACTIC ACID result: 1.72 09/08 ABG result: i-pH 7.52, i-Pco2 31, i-PO2 69, i-HCO3 25.6 09/08 troponin i result: 0.061 09/08 CTA PE impression: 1. Several segmental and numerous subsegmental acute pulmonary emboli. 2. Extensive patchy bilateral crazy paving type consolidation, nonspecific but likely in keeping with reported COVID 19. 3. Possible 7 mm nodule left upper lobe, consider 6 month follow-up. 4. Other findings as above. 09/09 SARS-COV-2 Variant Sequencing result: pending 09/09 FIBRINOGEN result: 491 09/09 DDIMER result: 26.69 09/09 ESR result: 9 09/10 FIBRINOGEN result: 399 09/10 DDIMER result: 13;30 09/10 procalcitonin result: 0.24 09/10 ESR result: 11 09/10 SARS-COV-2 Variant Sequencing result: pending 09/11 DDIMER result: 6.85 09/12 FIBRINOGEN result: 300 09/12 DDIMER result: 5.42 09/12 procalcintonin result: 0.14 09/12 ESR result: 19 09/13 DDMER result: 4.67 09/13 US LIVER impression: mild hepatomegaly. No sonographic evidence of hepatic steatosis or focal liver lesion. No intra or extrahepatic biliary ductal dilation. Small amount of gallbladder sludge. No cholelithiasis. 09/14 DDIMER result: 3.760 09/15 DDIMER result: 2.37 09/27 ALT/AST result: 99/39
pt recvd 2 doses of Engerix-B & was pregnant on 4APR92 @ time of the 2nd dose; 1MAY92 pt was aware of pregnancy;
Vaccine injection was given too high and forward of right arm; proper injection technique not used.  Excessive pain in shoulder area, radiating down the front of shoulder into armpit.
This case was reported by a physician via sales rep and described the occurrence of shingles in a male patient who received SHINGRIX for prophylaxis. Co-suspect products included SHINGRIX for prophylaxis. Previously administered products included ZOSTAVAX. On an unknown date, the patient received the 1st dose of SHINGRIX and the 2nd dose of SHINGRIX. On an unknown date, 213 days after receiving SHINGRIX and not applicable after receiving SHINGRIX, the patient experienced shingles, post herpetic neuralgia and product supply issue. On an unknown date, the outcome of the shingles and post herpetic neuralgia were not reported and the outcome of the product supply issue was unknown. It was unknown if the reporter considered the shingles and post herpetic neuralgia to be related to SHINGRIX. Additional details were reported as follows: The age at vaccination was not reported. The patient was a retired physician who spoke to sales representative at the GSK booth at the event. The patient stated that he had received his 1st dose of SHINGRIX 7 months before the date of reporting. The patient had not been able to get the second dose because of supply issue. The patient was at the time of reporting experiencing a case of shingles. The patient had pain in one dermatome near his abdomen but no rash.
Nausea; Swelling; Redness; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE SWELLING (Swelling), VACCINATION SITE ERYTHEMA (Redness) and NAUSEA (Nausea) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027A21A) for COVID-19 vaccination.     Concomitant products included HYDROCHLOROTHIAZIDE, METOPROLOL, METFORMIN and LISINOPRIL for an unknown indication.    On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Mar-2021, the patient experienced VACCINATION SITE SWELLING (Swelling) and VACCINATION SITE ERYTHEMA (Redness). On 21-Mar-2021, the patient experienced NAUSEA (Nausea). At the time of the report, VACCINATION SITE SWELLING (Swelling), VACCINATION SITE ERYTHEMA (Redness) and NAUSEA (Nausea) outcome was unknown. Unknown      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a elderly male patient who received SHINGRIX. Concomitant products included allopurinol, CRESTOR, FLOMAX, Levothyroxine, Losartan, Vitamin B12, Vitamin D3 and TYLENOL. In March 2018, the patient received the 1st dose of SHINGRIX .5 ml. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced injection site erythema, injection site swelling and injection site induration. The patient was treated with Cortisone Topical Cream. On an unknown date, the outcome of the injection site erythema, injection site swelling and injection site induration were recovered/resolved. The reporter considered the injection site erythema, injection site swelling and injection site induration to be related to SHINGRIX. Additional details were provided as follows: The reporter was wife of the patient. In end of March 2018, the patient received dose of SHINGRIX in right arm. The patient developed a large red and hard swollen area on his upper arm around the injection site. Caller reported that she applied cortisone cream to the area and that after 5 days the events were resolved.
About 12 hours after the jab, I started feeling body and muscle aches. This lasted 24-48 hours. I started experiencing urinary incontentene 48 hours later. Now. 72 hours later I still have frequent urge to urinate, but only a thimble full comes out. I feel the urgency to pee about every 10 minutes.
hands had a severe reaction that looked like psoriasis; skin there turned from soft (with never a problem) to very thick, hard, scaley red/purple/white; skin there turned from soft (with never a problem) to very thick, hard, scaley red/purple/white; The backs of my daughter's hands had a severe reaction that looked like psoriasis.  Her skin there turned from soft (with never a problem) to very thick, hard, scaley red/purple/white.; Although the texture has returned to normal, the color has scarred/remained; covid test result=Positive; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A 12 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 15Dec2021 15:00 (Lot number: FE3594) at the age of 12 years as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: COVID-19 (non-serious) with onset 18Dec2021, outcome "unknown", described as "covid test result=Positive"; PSORIASIS (non-serious) with onset 19Dec2021 09:00, outcome "recovered with sequelae", described as "hands had a severe reaction that looked like psoriasis"; SKIN HYPERTROPHY (non-serious), SKIN EXFOLIATION (non-serious) all with onset 19Dec2021 09:00, outcome "recovered with sequelae" and all described as "skin there turned from soft (with never a problem) to very thick, hard, scaley red/purple/white"; SKIN DISCOLOURATION (non-serious) with onset 19Dec2021 09:00, outcome "not recovered", described as "The backs of my daughter's hands had a severe reaction that looked like psoriasis.  Her skin there turned from soft (with never a problem) to very thick, hard, scaley red/purple/white."; SCAR (non-serious) with onset 19Dec2021 09:00, outcome "not recovered", described as "Although the texture has returned to normal, the color has scarred/remained". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of psoriasis, skin hypertrophy, skin exfoliation, skin discolouration, scar.  Additional information: Patient had no Covid prior to vaccination. She had no known allergies. Patient had no other vaccine in four weeks and no other medications in two weeks. Treatment included constant application of Vaseline and beeswax.
The baby was lethargic and would only sleep and breastfeed for 5 days following the vaccines. He also wouldn't make eye contact, smile or interact/respond to verbal stimuli for approximately 5 weeks. He did not respond to his parents, noises, toys, etc. Prior to the administration of the vaccines he had started to smile and make eye contact.
I have a red raised,feverish big heart shape rash at an below my injection site. 6 days later my arm is burning and hot to the touch.
received second dose on 5/8/21, too early. first dose given on 4/19/21
The patient had a red rash appear just below the injection site. The rash was slightly warm but not pain to the patient. Resolved without treatment.
Had side effects 4 hours after Pfizer booster. Stiff joints/painful.  Still sore-feet/knees/elbows.  Right knee and right hip.  Sharp pain.  Ankles hurt.  Getting up from sitting bothers.  Had trouble getting out of car.   No problems with previous vaccines.  No fever or chills.  Hot feeling started.  Seems to be getting more since.  Noted 1/10/21; as of 1/21/22 - Continues with significant limiting pain.  Notes ankles and knees bother her but also in all muscles below her waistline.  Advised blood work did not reveal an inflammatory cause of this pain.  holding  her Lipitor.
pt described itching throat, pt was given 25mg of diphenhydramine and recovered without additional complications
Patient called on 11/02 stating that her arm was very swollen, red, and uncomfortable. She states that it was painful and hot and that under her armpit there was tenderness.
Doses was administered on 09-Dec-2022 at 10:00AM, punctured on 08-Dec-2022 at 1:00 PM . First dose for patient aged was under 5 years old.; No adverse event; Doses was administered on 09-Dec-2022 at 10:00AM, punctured on 08-Dec-2022 at 1:00 PM . First dose for patient aged was under 5 years old.; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Doses was administered on 09-Dec-2022 at 10:00AM, punctured on 08-Dec-2022 at 1:00 PM . First dose for patient aged was under 5 years old.), PRODUCT STORAGE ERROR (Doses was administered on 09-Dec-2022 at 10:00AM, punctured on 08-Dec-2022 at 1:00 PM . First dose for patient aged was under 5 years old.) and NO ADVERSE EVENT (No adverse event) in an infant patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AS1214B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 09-Dec-2022 at 10:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Dec-2022 at 10:00 AM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Doses was administered on 09-Dec-2022 at 10:00AM, punctured on 08-Dec-2022 at 1:00 PM . First dose for patient aged was under 5 years old.). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Doses was administered on 09-Dec-2022 at 10:00AM, punctured on 08-Dec-2022 at 1:00 PM . First dose for patient aged was under 5 years old.) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Doses was administered on 09-Dec-2022 at 10:00AM, punctured on 08-Dec-2022 at 1:00 PM . First dose for patient aged was under 5 years old.), PRODUCT STORAGE ERROR (Doses was administered on 09-Dec-2022 at 10:00AM, punctured on 08-Dec-2022 at 1:00 PM . First dose for patient aged was under 5 years old.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Doses was administered on 09-Dec-2022 at 10:00AM, punctured on 08-Dec-2022 at 1:00 PM . First dose for patient aged was under 5 years old.) and PRODUCT STORAGE ERROR (Doses was administered on 09-Dec-2022 at 10:00AM, punctured on 08-Dec-2022 at 1:00 PM . First dose for patient aged was under 5 years old.).    Concomitant product use was not provided by the reporter. Patient age was under five years. It was reported that vial was initially thawed on 08-Dec-2022 and vial was  first punctured on 08-Dec-2022  at 1PM . Vial size was mentioned as 2.5 ml. The vial was initially stored in refrigerator on 08-Dec-2022. Vial was stored in room temperature post puncture. Vial exposed to room temperature for twenty one hours post puncture and room temperature range was in between 8 degree Celsius to 25 degree Celsius / 46 degree Fahrenheit to 77 degree Fahrenheit. Vial did not go any temperature excursions. Treatment information was not provided.
Post vax, the pt developed pneumococcal sepsis. The infant was hospitalized and recovered. Information from follow-up report states: A territory representative reported that a 3 month old infant received an injecton of Prevnar and subsequently developed pneumococcal sepsis. The infant was hospitalized and recovered. Follow-up information received from the physician on 22-Nov-2000, indicated that a 2 month old male received Prevnar, Acel-Imune, Hib-Titer, IPV and Recombivax-HB vaccines on 21-Aug-2000. On 12-Oct-2000, the infant developed pneumococcal sepis. A blood culture was positive for Streptococcs pneumonia, pencillin resistant. A copy of this report has been forward to manufactuer of IPV, and manufactuer of Recombivan-HB.
Red warm arm. 2.5 to 3'' to 1.5'' wide. Slightly raised- no pain- itches. Relieved with Benadryl.
Migraine, shooting pain throughout entire body, fever, nausea, chills, sweating
Very itchy, fine, papular red rash on left ventral side, just proximal to the crook of the elbow. 2 in. diameter